258 related articles for article (PubMed ID: 11874633)
1. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion.
Cheng WF; Hung CF; Hsu KF; Chai CY; He L; Polo JM; Slater LA; Ling M; Wu TC
Hum Gene Ther; 2002 Mar; 13(4):553-68. PubMed ID: 11874633
[TBL] [Abstract][Full Text] [Related]
2. Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity.
Cheng WF; Lee CN; Su YN; Chai CY; Chang MC; Polo JM; Hung CF; Wu TC; Hsieh CY; Chen CA
Cancer Gene Ther; 2006 Sep; 13(9):873-85. PubMed ID: 16645621
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen.
Cheng WF; Hung CH; Chai CY; Hsu KF; He L; Ling M; Wu TC
J Virol; 2001 Mar; 75(5):2368-76. PubMed ID: 11160740
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments.
Cheng WF; Hung CF; Hsu KF; Chai CY; He L; Ling M; Slater LA; Roden RB; Wu TC
Hum Gene Ther; 2001 Feb; 12(3):235-52. PubMed ID: 11177561
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene.
Cheng WF; Hung CF; Chai CY; Hsu KF; He L; Rice CM; Ling M; Wu TC
J Immunol; 2001 May; 166(10):6218-26. PubMed ID: 11342644
[TBL] [Abstract][Full Text] [Related]
6. Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles.
Lin CT; Hung CF; Juang J; He L; Lin KY; Kim TW; Wu TC
Mol Ther; 2003 Oct; 8(4):559-66. PubMed ID: 14529828
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity.
Kim TW; Hung CF; Kim JW; Juang J; Chen PJ; He L; Boyd DA; Wu TC
Hum Gene Ther; 2004 Feb; 15(2):167-77. PubMed ID: 14975189
[TBL] [Abstract][Full Text] [Related]
8. Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen.
Hung CF; He L; Juang J; Lin TJ; Ling M; Wu TC
J Virol; 2002 Mar; 76(6):2676-82. PubMed ID: 11861834
[TBL] [Abstract][Full Text] [Related]
9. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA.
Velders MP; McElhiney S; Cassetti MC; Eiben GL; Higgins T; Kovacs GR; Elmishad AG; Kast WM; Smith LR
Cancer Res; 2001 Nov; 61(21):7861-7. PubMed ID: 11691804
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand.
Hung CF; Hsu KF; Cheng WF; Chai CY; He L; Ling M; Wu TC
Cancer Res; 2001 Feb; 61(3):1080-8. PubMed ID: 11221836
[TBL] [Abstract][Full Text] [Related]
11. Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.
Cheng WF; Hung CF; Lee CN; Su YN; Chang MC; He L; Wu TC; Chen CA; Hsieh CY
Eur J Immunol; 2004 Jul; 34(7):1892-900. PubMed ID: 15214037
[TBL] [Abstract][Full Text] [Related]
12. Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects.
Chen CA; Chang MC; Sun WZ; Chen YL; Chiang YC; Hsieh CY; Chen SM; Hsiao PN; Cheng WF
Gene Ther; 2009 Jun; 16(6):776-87. PubMed ID: 19357714
[TBL] [Abstract][Full Text] [Related]
13. Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1).
Yang SG; Wo JE; Li MW; Mi FF; Yu CB; Lv GL; Cao HC; Lu HF; Wang BH; Zhu H; Li LJ
Vaccine; 2009 Dec; 27(52):7451-8. PubMed ID: 19450640
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC
Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449
[TBL] [Abstract][Full Text] [Related]
15. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.
Chen CH; Wang TL; Ji H; Hung CF; Pardoll DM; Cheng WF; Ling M; Wu TC
Gene Ther; 2001 Jan; 8(2):128-38. PubMed ID: 11313782
[TBL] [Abstract][Full Text] [Related]
16. Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis.
Cheng WF; Hung CF; Chen CA; Lee CN; Su YN; Chai CY; Boyd DA; Hsieh CY; Wu TC
Vaccine; 2005 May; 23(29):3864-74. PubMed ID: 15893626
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen.
Hsu KF; Hung CF; Cheng WF; He L; Slater LA; Ling M; Wu TC
Gene Ther; 2001 Mar; 8(5):376-83. PubMed ID: 11313814
[TBL] [Abstract][Full Text] [Related]
18. Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination.
Michel N; Osen W; Gissmann L; Schumacher TN; Zentgraf H; Müller M
Virology; 2002 Mar; 294(1):47-59. PubMed ID: 11886264
[TBL] [Abstract][Full Text] [Related]
19. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors.
Ji H; Wang TL; Chen CH; Pai SI; Hung CF; Lin KY; Kurman RJ; Pardoll DM; Wu TC
Hum Gene Ther; 1999 Nov; 10(17):2727-40. PubMed ID: 10584920
[TBL] [Abstract][Full Text] [Related]
20. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies.
Peng S; Trimble C; Ji H; He L; Tsai YC; Macaes B; Hung CF; Wu TC
J Biomed Sci; 2005 Oct; 12(5):689-700. PubMed ID: 16200349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]